TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Two patients whose care had been denied received approvals after taking their cases to insurance company leadership, according to MedPage Today’s report. The examples suggest escalation can draw attention to individual appeals, but the report does not establish how often it works or whether it is broadly available to patients.
Two patients whose care had faced insurance denials received coverage approvals after emailing senior company leaders, according to a MedPage Today report published Oct. 8. The cases, highlighted by former insurance executive Wendell Potter, show that escalating an appeal to a CEO’s office may prompt attention, but they do not establish that the approach works reliably or is accessible to most patients.
One case involved Elizabeth Nicholas, who was diagnosed with breast cancer at 36. After months of treatment, her insurer declined coverage for the type of chemotherapy her oncologist recommended. Nicholas emailed the company’s CEO and then received a message from its chief scientific officer saying the treatment had been approved, according to the report. Nicholas had previously written about her experience in Vanity Fair.
The other patient, Donald E. Grant Jr., had severe congenital cervical stenosis and developed myelomalacia after an earlier procedure did not adequately decompress his spinal cord. A planned operation with Hyun Bae of Cedars-Sinai was initially complicated by the surgeon’s out-of-network status, although the other elements of the operation were in-network. Grant’s case was approved at the in-network rate after he sent an appeal to UnitedHealth Group’s CEO and copied other company leaders, legislators and journalists.
Grant used Claimable, an AI-assisted appeal platform, to help assemble an 11-page submission. It argued that his insurer had no in-network surgeon with comparable qualifications, cited relevant regulations and requested that algorithms not be used to decide his case. The report says UnitedHealthcare approved the procedure with Bae at the in-network rate. It does not provide a broader dataset on executive escalations or compare their outcomes with standard appeals.
Executive Escalation Can Draw Attention
The cases matter to patients facing denials because they offer examples of an option beyond ordinary appeal channels: bringing a dispute to company leadership. Potter, a former insurance executive, told MedPage Today that large insurers have staff handling high-profile cases elevated to the C-suite or public-relations departments, and that those cases receive special attention. That is his account of company practices, not evidence that every CEO email produces a review or approval.
The approach also highlights an uneven burden. Preparing a detailed appeal takes time and research, and patients may need help understanding medical records, policy terms and regulations. Potter said few patients know how to challenge a denial effectively. A method that depends on persistence, contacts or media attention may be harder for people with fewer resources to use. The two accounts are individual outcomes, not a measure of how common successful escalation is.
Potter said clinicians may be positioned to help patients because of their familiarity with health care systems, but he also warned that repeatedly challenging insurers could carry risks for doctors. The report does not document a specific case of a physician being removed from a network for this reason. It does, however, frame executive escalation as a possible tactic rather than a replacement for an accessible, dependable review process.
AI-assisted medical appeal platform
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Two Appeals Reached Leaders
The cases reached leadership through different routes. Nicholas’s experience had received public attention after her account appeared in Vanity Fair; Potter noted to MedPage Today that, during his time at Cigna, cases being examined by a reporter were elevated. The report does not establish that media attention caused Nicholas’s approval, only that she emailed the CEO and later received word that the treatment was approved.
Grant’s submission was more formal and detailed. He used an AI-assisted platform to assemble medical and legal arguments, then sent the appeal to UnitedHealth Group’s CEO while copying others. The outcome followed that escalation, but the report does not say which specific argument or recipient led to approval. Both stories were featured by Potter in his Health Care Un-Covered newsletter.
Potter said patients and clinicians should not treat an initial denial as the final word. At the same time, he argued that resorting to the C-suite should not be necessary. Eagan Kemp, a health policy advocate at Public Citizen, told MedPage Today that patients and providers should not have to spend extensive time tracking down executives to secure care they consider medically necessary. Kemp linked frustration with these processes to support for Medicare for All, presenting that as a policy argument rather than a finding of the two cases.
“You can be certain that at big insurance companies, there is a group of people around the CEO who are dedicated to high-profile cases and cases that are elevated to the C-suite or to the PR department — and they get special attention.”
— Wendell Potter, former insurance company executive, speaking to MedPage Today
medical records organization software
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What These Cases Cannot Establish
The report describes two successful cases, but does not say how many patients email executives, how often those appeals result in approval, or whether the outcomes would have differed through standard appeals. It also does not give the insurers’ detailed explanations for the original denials or describe the full internal review process behind either approval.
It remains unclear how widely patients can use this strategy without help from journalists, clinicians, advocates or appeal-writing tools. The report also does not establish that copying legislators or reporters improves an appeal’s chances. Potter’s warning about possible consequences for doctors is a stated concern, not a confirmed outcome in the examples presented.
As an affiliate, we earn on qualifying purchases.
Appeals and Policy Debate Continue
The report does not identify a scheduled follow-up or a new policy change arising from the two approvals. Patients disputing coverage can continue to pursue the review options available through their insurer and applicable rules; the MedPage Today accounts offer executive contact as an additional tactic, not a guaranteed route to coverage. The details of each plan and denial matter, and the article does not provide individualized legal or medical advice.
Potter told MedPage Today that doctors may need to bring concerns to company leadership more often, while also saying that patients should not have to escalate cases that far. Kemp’s comments point to the broader debate over the administrative burden of obtaining care approvals and proposals to change the health system. Whether these two outcomes prompt wider use of executive escalation, or any response from insurers or policymakers, is not reported.
As an affiliate, we earn on qualifying purchases.
Key Questions
What happened in the two cases?
Both patients received coverage approvals after bringing their disputes to insurer leadership, according to MedPage Today. One sought coverage for recommended chemotherapy; the other sought an operation with an out-of-network surgeon at the in-network rate.
Did emailing a CEO guarantee the approvals?
No. The report recounts two individual outcomes and does not show that contacting an executive guarantees a result or works more often than standard appeal channels.
How did Donald Grant make his appeal?
Grant used Claimable, an AI-assisted appeal platform, to help prepare an 11-page submission with medical and legal arguments. He sent it to UnitedHealth Group’s CEO and copied company leaders, legislators and journalists.
What risks did the report identify?
Potter cautioned that doctors who frequently challenge an insurer could risk damaging their relationship with it, including possible network consequences. The report does not document that this happened to a clinician in either case.
What remains unknown about this strategy?
The report provides no data on how often executive appeals succeed, how many patients try them or which parts of the cases led to approval. It also does not establish whether the tactic is equally available to patients who lack time or professional assistance.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
